CTRI/2016/04/006854
进行中（未招募）
4 期
A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety of Zytiga�® (Abiraterone Acetate Tablets 250 mg) in IndianPatients With Metastatic, Castration-Resistant Prostate Cancer as Per Locally Approved Prescribing Information
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Health Condition 1: null- Indian participants with metastatic, castration-resistant prostate cancer will be enrolled in this study.
- 发起方
- Johnson Johnson Private Limited
- 状态
- 进行中（未招募）
- 最后更新
- 3年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Participants with established diagnosis of metastatic castration\-resistant prostate carcinoma
- •Being newly initiated on Zytiga treatment (abiraterone acetate tablets 250 mg) based on independent clinical judgment of treating physicians as per locally approved prescribing information
- •Willing to provide written informed consent indicating that they understand the purpose and are willing to participate in the post\-marketing
- •surveillance (PMS)
排除标准
- •Participants who are not eligible to receive Zytiga as per the locally approved prescribing information
- •Participants participating or planning to participate in any interventional drug trial during the course of this PMS
- •Contacts and
结局指标
主要结局
未指定
相似试验
已完成
4 期
Post Marketing Study of Perampanel in Patients with EpilepsyHealth Condition 1: G401- Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizuresCTRI/2019/01/016844Eisai Pharmaceutical India Limited200
尚未招募
4 期
Post marketing surveillance of Aripiprazole tabletHealth Condition 1: F209- Schizophrenia, unspecifiedCTRI/2022/01/039860Torrent Pharmaceuticals Limited
进行中（未招募）
1 期
Post marketing surveillance to collect safety information after vaccination with Bexsero administered in routine care and according to prescribing information in Korea.The study will collect real-world post-vaccination adverse events.EUCTR2023-000765-14-Outside-EU/EEAGlaxoSmithKline Biologicals SA
已完成
4 期
Superia: Sirolimus Eluting Coronary Stent System (SSECSS) India Post Marketing RegistryCTRI/2012/01/002393Innvolution Med System200
已完成
4 期
Postmarketingstudy to monitor safety of golimumab injection 50milligram (mg) in Indian subjects with Rheumatoid Arthritis (RA)Health Condition 1: null- Indian participants with Rheumatoid Arthritis will be enrolled in the studyCTRI/2016/04/006867Johnson Johnson Private Limited120